


# Introduction to mRNA-seq Analysis

*Rosalba Giugno  
Simone Avesani  
Manuel Tognon*





# Transport derived Ultrafines and the Brain Effects (TUBE)

<https://www.tube-project.eu/>


*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 814978 (TUBE).*



# TUBE's Partners

Many partners each of one specialized in a different experimental phase:

- **Finland:** sample collection and library preparation
- **Czech Republic:** sequencing, epigenetics
- **Italy (Verona):** data analysis



# Alzheimer's Disease

*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 814978 (TUBE).*



# Alzheimer's Disease

- Neurodegenerative disease
- Irreversible disease
- Average life expectancy is 10 years



# Alzheimer's Disease


- Neurodegenerative disease
- Irreversible disease
- life expectancy is 10 years

Main symptoms:

- loss of memory
- repetitive or impulsive behavior
- loss of physical abilities
- loss of memory smell



# Challenges

- There is no cure
- There is no a diagnostic test  exclusion of all other pathologies
- It is very difficult to study the evolution of the disease



# Goal of the experiment



Try to find an innovative way to study the Alzheimer's disease evolution



Discover a potential way to diagnose the disease





# Goal of the experiment



Try to find an innovative way to study the Alzheimer's disease evolution




Discover a potential way to diagnose the disease



Starting from the Olfactory Mucosa



# Olfactory Mucosa



- Divide nose cavity from the brain
- The odors perception take place



loss of memory smell


# What to do?

*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 814978 (TUBE).*



# What to do?

- **STEP 1:** take OM samples with biopsy from healthy, sick and mild cognitive subjects



Group	ID	gender	age when biopsied	ApoE genotype
control (10)	102	female	78	34
	105	female	73	33
	106	male	67	34
	108	female	73	34
	109	male	64	34
	110	female	72	33
	111	female	72	33
	112	female	73	33
	113	female	70	33
	115	male	68	33

Group	ID	gender	age when biopsied	ApoE genotype
MCI (11)	201	male	82	34
	205	male	77	34
	207	male	68	33
	208	male	63	34
	209	male	72	23
	210	female	72	33
	212	female	73	22
	213	female	72	33
	214	female	76	33
	215	female	62	34
	216	male	63	44

Group	ID	gender	age when biopsied	ApoE genotype
AD (12)	301	female	64	33
	302	male	80	33
	303	female	67	44
	304	female	58	44
	305	female	80	33
	306	female	75	44
	307	male	71	44
	308	male	61	34
	309	female	67	44
	311	male	60	33
	313	male	65	44
	314	male	71	34

# What to do?

- **STEP 2:** sequence the genomic content of the cells sampled

**NB: different type of sequencing!**



# Bulk vs Single Cell sequencing

*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 814978 (TUBE).*




# Bulk vs Single Cell sequencing


**Bulk**



**Single Cell**



# Bulk vs Single Cell sequencing





# What to do?

**STEP 3:** search if there are genomic differences between healthy and sick samples



**Genes more or less expressed in sick subjects respect to healthy subjects!**

# Pipeline



Sequencing





Quality Control




Pre-processing



Quality Control after pre-processing



# Pipeline



Alignment



Quantification



R analysis



Differential expression analysis

